Serum test for assessment of patients with Bence Jones myeloma.
about
Appraisal of immunoglobulin free light chain as a marker of responsePrognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging systemRenal clearance of quantum dots.Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significanceHigh serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisImmunoglobulin free light chains and solitary plasmacytoma of boneInternational Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantationSmoldering multiple myeloma.Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis - a pilot studySerum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.Lymphoproliferative disease-related mixed cryoglobulinemia treated with rituximab and prednisoloneHigh-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort studyThe 4C5 cell-impermeable anti-HSP90 antibody with anti-cancer activity, is composed of a single light chain dimerDiagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests.Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.The evolving use of serum free light chain assays in haematology.Comment on "Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy"Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome.Serum N-Glycans: A New Diagnostic Biomarker for Light Chain Multiple Myeloma.Genetic events in the pathogenesis of multiple myeloma.Early Application of High Cut-Off Haemodialysis for de-Novo Myeloma Nephropathy is Associated with Long-Term Dialysis-Independency and Renal Recovery.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma.A clinical decision rule to aid ordering of serum and urine protein electrophoresis for case-finding of paraproteins in hospitalized inpatients.Screening panels for detection of monoclonal gammopathies.International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myelomaSerum free light chain analysis in multiple myeloma and plasma cell dyscrasias.Guidelines for the diagnosis and management of multiple myeloma 2011.Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.The importance of screening for serum free light chains in suspected cases of multiple myeloma and their impact on the kidney.The serological diagnostic challenges of multiple myeloma.Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma.Serum-free light-chain analysis in diagnosis and management of multiple myeloma and related conditions.Serum free light chain assays not total light chain assays are the standard of care to assess Monoclonal Gammopathies.Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions.Association of immunoglobulin G4 and free light chain with idiopathic pleural effusion.The spot urine protein/creatinine ratio is a simple, rapid and inexpensive method for monitoring patients with light-chain multiple myelomaEarly Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation.Assessment of free light chains in HCV-positive patients with mixed cryoglobulinaemia vasculitis undergoing rituximab treatment.
P2860
Q24624398-FB9C9AC7-B4F6-4079-801D-678157BB3823Q24653434-44B1DBBE-962A-4A97-9194-F82E926F93ADQ24657265-196D57C7-567F-41E1-BA7B-8F7CDF6A4854Q24669898-A0A3C626-94FC-46AD-A838-2185C34CE2B8Q24670135-E567AD90-6CEC-46BB-83C5-CEFF2062F7B1Q24685868-19B915D7-0455-46ED-B0AA-BE00B1E8C7C3Q27002668-06617C8B-451D-4701-B11B-A52DE03D0BE3Q28082855-A60A6BB5-C2C4-4873-98DC-6FC726B69BBCQ33301492-41EF0DB5-FAA0-4937-A58C-58F8C016EF74Q33371085-24B39242-B9C4-4AEE-A6EA-85605864185DQ33628235-1E167C26-A7F3-41FA-91D5-E7BAAA34D3BFQ33952837-01DCD608-C109-4415-9E28-3FA59DE048DCQ33997173-98BA84F1-2426-4B5D-BAE1-A90B986D9775Q34017774-608CC741-2DE0-4810-ABBC-67D9F8D5CA6FQ34557435-1D915E55-6AC4-4C87-A636-82019661664FQ34615704-CABB0B40-C820-4342-88DA-F63A82751692Q34758218-8328A854-DC6D-4FC6-83E2-2FAD8AF0529DQ35226933-6DCA1BC3-0C62-473A-B561-10F1400CBD2BQ35638270-08B9949B-CD39-41D4-850B-1FFA25F6D0D4Q35663623-E8D5F25D-65F8-4DEA-BA2A-4786C9ACCBDBQ36380235-AF7DB33D-E7F4-4A7B-AEDD-BABE76FD6ADCQ36556014-8C74BBF0-4DEC-4AEF-B52B-14BBCE0B426DQ36777247-C35A6BF2-34F8-4DAB-986C-699143163655Q36870457-1E9D7615-DAD3-4A4E-8AEB-7C5FF5A9D468Q37172007-C7388366-806D-4E5C-A6BA-4DF796DFF824Q37507513-7D86CA0F-F131-4B08-90F0-F21E83A157CFQ37528072-1FADCF43-0170-47C4-AC23-CEE46C2E7268Q37821496-0F1744E7-28B8-4511-9164-C9455C4CA65FQ37875193-72E43735-9AF7-4E3D-8245-2709407B6571Q38168869-172F2A88-CD51-4A9F-B30E-5515958F3A11Q38261185-CBE71957-E7AB-46C1-80DC-976C6686E3D0Q38351789-0B2127DF-1395-406E-AFD8-76BCF249AD57Q38398899-2EFCEC61-7385-465D-A5D3-C7D2F4848DC0Q38911216-693FE085-0BC0-49AF-BEB6-8E671619560AQ38917341-113D3146-22B9-48EA-8730-EFFED8ADF35BQ39932145-FA2B3ADF-3D37-4976-9BF8-C8875FFC2B35Q40171169-33701E4D-48BD-4E9E-8E91-B941A581562CQ40332106-827623E3-0EA9-439B-AE19-20C4E91D1437Q40368431-EBDF1298-EA60-45D6-B3B5-307D689FFBEFQ41175619-36800A52-FB7C-488E-A21A-6B8A75CE0B66
P2860
Serum test for assessment of patients with Bence Jones myeloma.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Serum test for assessment of patients with Bence Jones myeloma.
@ast
Serum test for assessment of patients with Bence Jones myeloma.
@en
Serum test for assessment of patients with Bence Jones myeloma.
@nl
type
label
Serum test for assessment of patients with Bence Jones myeloma.
@ast
Serum test for assessment of patients with Bence Jones myeloma.
@en
Serum test for assessment of patients with Bence Jones myeloma.
@nl
prefLabel
Serum test for assessment of patients with Bence Jones myeloma.
@ast
Serum test for assessment of patients with Bence Jones myeloma.
@en
Serum test for assessment of patients with Bence Jones myeloma.
@nl
P2093
P1433
P1476
Serum test for assessment of patients with Bence Jones myeloma.
@en
P2093
Arthur R Bradwell
Graham P Mead
Hugh D Carr-Smith
Mark T Drayson
Timothy C Harvey
P304
P356
10.1016/S0140-6736(03)12457-9
P407
P577
2003-02-01T00:00:00Z